Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

被引:0
作者
Matteo Santoni
Alessandro Rizzo
Jakub Kucharz
Veronica Mollica
Matteo Rosellini
Andrea Marchetti
Elisa Tassinari
Fernando Sabino Marques Monteiro
Andrey Soares
Javier Molina-Cerrillo
Enrique Grande
Nicola Battelli
Francesco Massari
机构
[1] Macerata Hospital,Oncology Unit
[2] Istituto Tumori Giovanni Paolo II-Bari,Struttura Semplice Dipartimentale Di Oncologia Medica Per La Presa in Carico Globale del Paziente Oncologico ″Don Tonino Bello″, Istituto Di Ricerca E Cura a Carattere Scientifico (IRCCS)
[3] Maria Sklodowska-Curie National Research Institute of Oncology,Department of Uro
[4] IRCCS Azienda Ospedaliero-Universitaria Di Bologna,Oncology
[5] University of Bologna,Medical Oncology
[6] Latin American Cooperative Oncology Group - LACOG,Department of Experimental, Diagnostic and Specialty Medicine
[7] Hospital Santa Lucia,Oncology and Hematology Department
[8] Latin American Cooperative Oncology Group - LACOG,Department of Medical Oncology
[9] Hospital Israelita Albert Einstein,Department of Medical Oncology
[10] Centro Paulista de Oncologia/Oncoclínicas,undefined
[11] Hospital Ramón Y Cajal,undefined
[12] MD Anderson Cancer Center Madrid,undefined
来源
Cancer Immunology, Immunotherapy | 2023年 / 72卷
关键词
Pembrolizumab; Cancer; Complete response; Immuno-oncology combinations; Immunotherapy; Meta-analysis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1365 / 1379
页数:14
相关论文
共 475 条
[1]  
Borcoman E(2019)Novel patterns of response under immunotherapy AnnOncol 30 385-396
[2]  
Kanjanapan Y(2020)Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: a systematic review on reporting of methods in randomized controlled trials PLoS ONE 15 3801-11
[3]  
Champiat S(2020)A decade of immune-checkpoint inhibitors in cancer therapy Nat Commun 11 1-270
[4]  
Faury S(2018)Immune checkpoint inhibitors: recent progress and potential biomarkers Exp Mol Med 50 265-251
[5]  
Foucaud J(2005)Combining immunotherapy with chemotherapy to treat cancer Discov Med 5 237-1823
[6]  
Robert C(2012)Combining immunotherapy and targeted therapies in cancer treatment Nat Rev Cancer 12 1813-7
[7]  
Darvin P(2015)Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol 26 132-41
[8]  
Toor SM(2016)RECIST 1. 1-Update and clarification: from the RECIST committee Eur J Cancer 62 336-2121
[9]  
Sasidharan Nair V(2010)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Int J Surg 8 2108-2301
[10]  
Elkord E(2018)Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer N Engl J Med 379 2288-757